In Hamburg, a vaccine against COVID-19 is currently being tested for its safety, tolerability and specific immune response against the new pathogen. (Image: Photo Sesaon / stock.adobe.com)
COVID-19 vaccine is being tested
A few weeks ago, the University Medical Center Hamburg-Eppendorf (UKE) received approval to start clinical trials of a vaccine against COVID-19. The first participants in the study have now been vaccinated against the SARS-CoV-2 coronavirus.
According to experts, the danger posed by the SARS-CoV-2 coronavirus can be avoided if a vaccination against the new pathogen is available. Scientists around the world are working on vaccines. One of them is currently being tested on people in Germany.
Start of clinical trial
According to a recent press release, Friday, October 9, the first female volunteer was injected with the MVA-SARS-2-S vaccine against COVID-19. A total of six subjects are reported to have received the vector vaccine to date.
The Hamburg-Eppendorf University Medical Center (UKE) received approval from the Paul Ehrlich Institute, the Federal Institute for Vaccines and Biomedical Medicines and the Ethics Committee of the Hamburg Medical Association at the end of September for start clinical trials of the vaccine.
So far everything is going as planned
The vaccine was developed by scientists from the German Infection Research Center (DZIF) and IDT Biologika GmbH and is currently being investigated in clinical phase I for its safety, tolerability and specific immune response against the new pathogen. .
Preliminary examinations and the selection of healthy volunteers began in early October, before the first person tested was vaccinated on October 9. With the necessary margin of safety, other people were vaccinated. “So far everything has gone as planned and as planned,” explains Prof. Dr. Marylyn Addo, Head of Infectious Diseases at UKE, who is the investigator in charge of the clinical trial
Formation of antibodies and T cells
According to the information, a total of 30 subjects between the ages of 18 and 55 will be vaccinated in eight groups and in two increasing doses. Study participants receive two vaccinations every four weeks and are medically monitored for a few hours after vaccinations at the CTC North contract medical institute at UKE.
In the days following vaccinations and for the next six months, participants should attend regular outpatient follow-up exams to check the vaccine’s tolerance, possible side effects and immune response based on blood tests and surveys. .
Scientists in Prof. Addo’s task force and partner DZIF in Marburg are simultaneously measuring antibody and T cell formation in the body and comparing them with the immune response of recovered COVID-19 patients. (a d)
Author and source information
This text complies with the requirements of specialized medical literature, medical directives and current studies and has been verified by health professionals.
This article is provided for informational purposes only and should not be used for self-diagnosis or self-treatment. It cannot replace a visit to the doctor.